‘ Is life worth living? It all depends on the liver’ (American philosopher William James [1842—1910]) Non-alcoholic fatty liver disease (NAFLD) is currently the most frequent global liver disease.1 ...

Randomised controlled trials (RCTs) have shown that computer-aided detection (CADe) can significantly improve adenoma detection rates (ADRs). In contrast, implementation studies did not show ADR ...

Background Endoscopic procedures are a notable source of medical waste, contributing significantly to environmental pollution ...

Background Chronic inflammation and elevated reactive oxygen species are key contributors to hepatocellular carcinoma (HCC) ...

Background Metabolic dysfunction-associated steatotic liver disease (MASLD) affects over 30% of the general population and is ...

Objective Ample evidence exists for the role of abnormal gut microbiota composition and increased gut permeability (‘leaky gut’) in chronic inflammation that commonly co-occurs in the gut in both ...

Background GPR171 suppresses T cell immune responses involved in antitumour immunity, while its role in inflammatory bowel disease (IBD) pathogenesis remains unclear. Objective We aimed to investigate ...

Results DUOX2 activity increased permeability and bacterial translocation and induced subclinical inflammation in vTLR4 mice. GF vTLR4 mice had increased DUOX2 activity and permeability but no ...

Objective The purpose of this study is to develop an anti-PDL1-based interferon (IFN) fusion protein to overcome the chronic hepatitis B virus (HBV)-induced immune tolerance, and combine this ...

Over 2.5 million gastrointestinal endoscopic procedures are carried out in the United Kingdom (UK) every year. Procedures are carried out with local anaesthetic r with sedation. Sedation is commonly ...

Adult patients with severe chronic small intestinal dysmotility are not uncommon and can be difficult to manage. This guideline gives an outline of how to make the diagnosis. It discusses factors ...

Objective Programmed death 1 and its ligand 1 (PD-1/PD-L1) immunotherapy is promising for late-stage lung cancer treatment, however, the response rate needs to be improved. Gut microbiota plays a ...